Effects of thymosin α 1 combined with ulinastatin immunomodulatory therapy on sepsis
Objective To analyze the clinical effects of thymosin α1 combined ulinastatin immunomodulatory therapy in the treatment of sepsis(SS).Methods 110 SS patients were divided into 2 groups using the touch ball method,with 55 cases in each group.The control group were received classic treatment in the Battle to Save Sepsis(SSC),while the observation group were received thymosin α1.The clinical efficacy,inflammatory factors,the mos item short from healthy survy(SF-36)score,and blood gas indicators were compared between two groups of patients.Result After treatment,the total effective rate of the observation group was 98.18%,which was higher than the control group's 81.82%,and the difference was statistically significant(P<0.05).After 10 d of treatment,the levels of blood gas indicators in the observation group were higher than those in the control group,and the levels of PaO2 and SaO2 were lower than those in the control group(P<0.05).After 10 d of treatment,the levels of hs-CRP,PCT,IL-6 and TNF-α in the observation group were lower than those in the control group(P<0.05).After 10 d of treatment,the levels of CD3+,CD4+,CD8+,CD4+/CD8+in the observation group were lower than those in the control group(P<0.05).The SF-36 score of the observation group was higher than that of the control group(P<0.05).Conclusion The application of thymosin α1 combined with ulinastatin in the treatment of SS patients has a definite effect,which can quickly improve the patient's blood gas indicators and immune function,control inflammatory reactions,and facilitate prognosis.
万方数据
维普
